It lowers blood glucose and increases insulin sensitivity, thereby reducing insulin resistance
Within the GLP-1RA group, discontinuing treatment for even 0.5 years was associated with a higher MACE risk compared to continued use
Switzer NJ, Karmali S, Gill RS, et al
Pattern 1: Continue at the therapeutic dose This is what the trial data supports most strongly
Marston, Eastern District of Pennsylvania Number of Cases: Approximately 2,947 pending cases (and growing rapidly) Defendants: Novo Nordisk and Eli Lilly Covered Drugs: Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Victoza, Saxenda, Trulicity Key Developments: August 15, 2025 - Landmark Ruling: Judge Marston ruled that gastroparesis claims require objective diagnostic testing (gastric emptying scan)